More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from weight-loss and ...

Key Takeaways ・The weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer. ・Tumor size closely matched body weight and fat levels, suggesting fat ...

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...

Researchers followed 60,000 adults aged 40 and older—who took various types of antidiabetic medication—for seven years ...

A cutting-edge mouse study reveals that tirzepatide, the dual GLP-1/GIP drug already hailed for impressive weight loss, does more than trim fat: it slashes the growth of obesity-linked breast tumors.